X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Results of Phase 1 clinical trials showed no serious adverse events with infusion of TY027 in healthy volunteers, and researchers evaluated up to the 30 mg/kg dose.
Lead Product(s): TY027
Therapeutic Area: Infections and Infectious Diseases Product Name: TY027
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 10, 2020
Details:
Data published in the New England Journal of Medicine demonstrate that TY014 was not only safe and well tolerated at the highest doses tested, but also completely eradicated the yellow fever virus in the bloodstream of all participants within 48 hours of infusion.
Lead Product(s): TY014
Therapeutic Area: Infections and Infectious Diseases Product Name: TY014
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 30, 2020
Details:
The study to be conducted by Tychan is meant to determine the safety and effectiveness of TY027, a monoclonal antibody or immune system protein that specifically targets Sars-CoV-2, the virus that causes Covid-19.
Lead Product(s): TY027
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 10, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
